Top Story

Breast Mammo Social
Artificial Intelligence
AI model could prevent unnecessary treatment for breast cancer patients, says study
Breast cancer patients could be spared unnecessary chemotherapy with the use of a new artificial intelligence (AI) tool that helps predict survival risk, say researchers.
Featured
Crispr Cas9 Gene Editing Social
FDA Clearance
KSQ Therapeutics receives FDA clearance for trial of CRISPR-Cas9 engineered tumor therapy
Brain Abstract Social
Vascular Disease
Potential drug target to prevent small vessel disease identified in study
Latest News
Business Graph Money Stocks Social
Candel Therapeutics to lay off 50% of workforce, refocus on advanced oncology immunotherapies
November 28, 2023
Blood Test Samples Lab Social
Scipher Medicine, Quest Diagnostics collaborate on RA diagnostics
November 28, 2023
Dna Sequence Social
Nanopore sequencing slashes tumor analysis times and costs
November 28, 2023
Heart Pulmonary Trunk Social
AI-powered blood test supports risk stratification of heart disease patients
November 27, 2023
Business Graph Money Stocks Social
Trends and Finance
Candel Therapeutics to lay off 50% of workforce, refocus on advanced oncology immunotherapies
Stock
Nasdaq issues delisting notice to T2 Biosystems
Regulatory Guidance
AMP, other stakeholders urge Congress to pause FDA LDT rule, update CLIA
Regulatory Approval
U.K. regulators approve "world-first" sickle-cell gene therapy
Dna Sequence Social
Sequencing
Nanopore sequencing slashes tumor analysis times and costs
Coronary Artery Disease
AI-powered blood test supports risk stratification of heart disease patients
Synthetic Biology
Bit.bio unveils cell therapy candidate for liver conditions
Regulatory Approval
U.K. regulators approve "world-first" sickle-cell gene therapy
Brain Abstract Social
Vascular Disease
Potential drug target to prevent small vessel disease identified in study
Rheumatoid Arthritis
Scipher Medicine, Quest Diagnostics collaborate on RA diagnostics
Sequencing
Nanopore sequencing slashes tumor analysis times and costs
Coronary Artery Disease
AI-powered blood test supports risk stratification of heart disease patients
More from LabPulse.com
Nasdaq issues delisting notice to T2 Biosystems
T2 Biosystems has received a delisting notice from Nasdaq after failing to satisfy the minimum $35 million market value of listed securities threshold required to remain listed.
November 27, 2023
Stock Exchange Social
Siemens Healthineers contracts with NIAID to develop NGS-based sepsis test
Siemens Healthineers has secured a three-year, $5.5 million contract with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health, to develop a test to improve sepsis treatment.
November 22, 2023
Sepsis Bacteria Social
Universal DX partners with Quest Diagnostics, closes $70M series B financing round
Liquid biopsy firm Universal DX and Quest Diagnostics have formed a strategic collaboration under which Quest will exclusively offer services for Universal DX’s Signal-C colorectal cancer screening test in the U.S.
November 21, 2023
Colorectal Cancer Social
Bit.bio unveils cell therapy candidate for liver conditions
Synthetic biology company bit.bio has unveiled a lead cell therapy candidate as a treatment for life-threatening liver conditions, and it has set out its broader cell therapy pipeline.
November 22, 2023
Liver Anatomy Social
AMP, other stakeholders urge Congress to pause FDA LDT rule, update CLIA
The Association for Molecular Pathology (AMP) requested Congress to update the Clinical Laboratory Improvement Amendments (CLIA) as an alternative to the FDA’s proposed rule to increase agency oversight of laboratory-developed tests (LDTs).
November 22, 2023
Washington Dc Capitol Social
U.K. regulators approve "world-first" sickle-cell gene therapy
U.K. medical regulators have approved a “world-first” gene therapy that aims to cure two blood disorders: sickle cell disease and transfusion-dependent β-thalassemia. They are the first regulatory body to approve the treatment.
November 20, 2023
Sickle Cell Anemia2 Social
AI concurs with humans in heart failure test, suggesting scalable approach to clinical trials
Artificial intelligence (AI) may make clinical trials more efficient by accurately identifying events at scale, a retrospective analysis has found.
November 21, 2023
Computer Heart Social
Nanopore Technologies, Day Zero Diagnostics to collaborate on sepsis diagnostic solution
Oxford, U.K.-based Oxford Nanopore Technologies and Boston-based infectious disease diagnostics firm Day Zero Diagnostics have announced a partnership to develop an end-to-end solution for the diagnosis of bloodstream infections.
November 20, 2023
Bacteria Blood Sepsis Social
10x Genomics awarded $31M in patent infringement lawsuit against NanoString Technologies
10x Genomics has been awarded more than $31 million in damages by a jury in the U.S. District Court for the District of Delaware in its patent infringement lawsuit against NanoString Technologies.
November 20, 2023
Gavel Money Social
Exact Sciences files patent infringement lawsuit against Geneoscopy
Exact Sciences has filed a patent infringement lawsuit against Geneoscopy alleging that Geneoscopy’s recently launched colorectal screening test infringes on a patented method used in Exact Science’s Cologuard assay.
November 17, 2023
Lawsuit Social
Verici DX, Thermo Fisher Scientific sign licensing agreement on pre-transplant prognostic test
Transplant diagnostic firm Verici DX and Thermo Fisher Scientific have signed an exclusive global licensing and commercialization agreement to develop a pre-transplant prognostic test for early kidney rejection risk assessment.
November 17, 2023
Kidneys Closeup Social
FDA plans to increase oversight of LDTs garner strong response
Plans to increase U.S. Food and Drug Administration (FDA) oversight of laboratory-developed tests (LDTs) have drawn a strong response from trade groups, individuals, and organizations.
November 17, 2023
Fda Sign Dc Social